Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
McKinsey
McKesson
Express Scripts
Merck

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Bevacizumab - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for bevacizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 3
Yanhong DengPhase 3
China Medical University HospitalPhase 2

See all bevacizumab clinical trials

Recent Litigation for bevacizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
Genentech, Inc. v. Pfizer Inc.2019-04-05
Genentech, Inc. v. Immunex Rhode Island Corp.2019-03-29

See all bevacizumab litigation

PTAB Litigation
PetitionerDate
Forty Seven, Inc.2018-01-08
Pfizer Inc.2018-01-05
Hospira, Inc.2016-09-09

See all bevacizumab litigation

Company Disclosures: US Patents for bevacizumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Biogen, Inc. (Cambridge, MA) 2020-08-05 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Biogen, Inc. (Cambridge, MA) 2020-08-05 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for bevacizumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for bevacizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
780 Luxembourg   Start Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
23/2006 Austria   Start Trial PRODUCT NAME: NATALIZUMAB
06/025 Ireland   Start Trial PRODUCT NAME: NATALIZUMAB (ALSO KNOWN AS TYSABRI); REGISTRATION NO/DATE: EU/1/06/346/001 20060627
14C/037 Belgium   Start Trial PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Johnson and Johnson
Moodys
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.